Management of Advanced Prostate Cancer in the Precision Oncology Era.
Management of Advanced Prostate Cancer in the Precision Oncology Era.
复制标题
作者：
这篇综述文章详细介绍了用于治疗晚期前列腺癌的基于肿瘤学的新的精确疗法。转移性去势抵抗性前列腺癌仍然是一种无法治愈的诊断，但是新发现的生物标志物已经扩大了一些疾病进展患者的治疗范围。详细介绍了免疫检查点抑制剂、利用DNA损伤反应缺陷的治疗方法以及放射性配体疗法和治疗诊断学的新创新。这篇文章强调了精确肿瘤学的潜在和现实应用，通过针对每个患者肿瘤的个体特征进行定制治疗来改善前列腺癌患者的预后。前列腺癌（PC）是美国男性癌症死亡的第二大原因。虽然侵袭性PC的多样化和改进的治疗选择改善了患者结局，但转移性去势抵抗性前列腺癌（mCRPC）仍然无法治愈，并且是研究治疗兴趣的领域。本综述将涵盖支持新的精确肿瘤学为基础的治疗方法的适应症的开创性临床数据，并探讨其局限性，目前的效用和治疗PC的潜力。在过去的十年中，高危和晚期PC的全身治疗经历了重大发展。生物标记物驱动的治疗使该领域更接近能够为每位患者实施精确肿瘤治疗的目标。Pembrolizumab（PD-1抑制剂）的肿瘤不可知批准标志着这一方向的重要进展。还有几种PARP抑制剂适用于DNA损伤修复缺陷的患者。此外，用于成像和治疗的治疗诊断剂进一步彻底改变了PC的治疗前景，代表了精准医学的另一个进步。放射性标记的前列腺特异性膜抗原（PSMA）PET/CT正迅速成为诊断的标准护理，PSMA靶向放射性配体疗法最近已获得FDA批准用于转移性前列腺癌。这些进展在精确为基础的肿瘤学详细介绍了这一审查。
This review article details new precision oncology-based therapeutics used to treat advanced prostate cancer. Metastatic castration-resistant prostate cancer remains an incurable diagnosis, however newly identified biomarkers have expanded treatment repertories for some patients with progressive disease. Advancements in immune checkpoint inhibitors, therapeutics that exploit DNA damage response deficiencies, and new innovations in radioligand therapies and theranostics are detailed. This article highlights the potential and real-world application of precision oncology to improve outcomes for patients with prostate cancer by tailoring treatment to the individual characteristics of each patient’s tumor. Prostate cancer (PC) is the second leading cause of cancer death in men in the United States. While diversified and improved treatment options for aggressive PC have improved patient outcomes, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and an area of investigative therapeutic interest. This review will cover the seminal clinical data supporting the indication of new precision oncology-based therapeutics and explore their limitations, present utility, and potential in the treatment of PC. Systemic therapies for high-risk and advanced PC have experienced significant development over the past ten years. Biomarker-driven therapies have brought the field closer to the goal of being able to implement precision oncology therapy for every patient. The tumor agnostic approval of pembrolizumab (a PD-1 inhibitor) marked an important advancement in this direction. There are also several PARP inhibitors indicated for patients with DNA damage repair deficiencies. Additionally, theranostic agents for both imaging and treatment have further revolutionized the treatment landscape for PC and represent another advancement in precision medicine. Radiolabeled prostate-specific membrane antigen (PSMA) PET/CT is rapidly becoming a standard of care for diagnosis, and PSMA-targeted radioligand therapies have gained recent FDA approval for metastatic prostate cancer. These advances in precision-based oncology are detailed in this review.
登录
查看更多内容
影响因子：
5.8
作者：
Anscher, Mitchell S.;Chang, Elaine;Beaver, Julia A.
通讯作者：
Beaver, Julia A.
具有转移性cast割前列腺癌的男性的鲁卡巴里（Rucaparib）具有BRCA1或BRCA2基因改变。
DOI：
10.1200/jco.20.01035
发表时间：
2020-11-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Abida W;Patnaik A;Campbell D;Shapiro J;Bryce AH;McDermott R;Sautois B;Vogelzang NJ;Bambury RM;Voog E;Zhang J;Piulats JM;Ryan CJ;Merseburger AS;Daugaard G;Heidenreich A;Fizazi K;Higano CS;Krieger LE;Sternberg CN;Watkins SP;Despain D;Simmons AD;Loehr A;Dowson M;Golsorkhi T;Chowdhury S;TRITON2 investigators
通讯作者：
TRITON2 investigators
铂敏感转移性去势抵抗性前列腺癌中 BRCA2 的双等位基因失活。
影响因子：
23.4
作者：
Cheng HH;Pritchard CC;Boyd T;Nelson PS;Montgomery B
通讯作者：
Montgomery B
影响因子：
82.9
作者：
Davies H;Glodzik D;Morganella S;Yates LR;Staaf J;Zou X;Ramakrishna M;Martin S;Boyault S;Sieuwerts AM;Simpson PT;King TA;Raine K;Eyfjord JE;Kong G;Borg Å;Birney E;Stunnenberg HG;van de Vijver MJ;Børresen-Dale AL;Martens JW;Span PN;Lakhani SR;Vincent-Salomon A;Sotiriou C;Tutt A;Thompson AM;Van Laere S;Richardson AL;Viari A;Campbell PJ;Stratton MR;Nik-Zainal S
通讯作者：
Nik-Zainal S
DOI：
10.1158/1078-0432.ccr-12-3791
发表时间：
2013-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Aparicio AM;Harzstark AL;Corn PG;Wen S;Araujo JC;Tu SM;Pagliaro LC;Kim J;Millikan RE;Ryan C;Tannir NM;Zurita AJ;Mathew P;Arap W;Troncoso P;Thall PF;Logothetis CJ
通讯作者：
Logothetis CJ